

AMENDMENTS TO THE CLAIMS

1-43. Canceled.

44. (Currently Amended) A method of preventing inhibiting at least one of tumor cellular invasion and tumor metastasis in a mammal, the method comprising administering an effective amount of at least one of:

i. NNN'N'-Tetrakis-(2-pyridyl-methyl)-ethylenediamine (TPEN); and

ii. a TPEN derivative, wherein said TPEN derivative is selected from the group consisting of ethylenediamine, diethylenetriamine, triethylenetetramine, ethylenediamine, diethylenetriamine, triethylenetetramine, triethylenediamine, tetraethylenepentamine, aminoethylethanol amine, aminoethylpiperazine, pentaethylenehexamine, triethylenetetramine-hydrochloride, tetraethylenepentamine-hydrochloride, pentaethylenehexamine-hydrochloride, tetraethylpentamine, captopril, and penicilamine;

to said mammal.

45. (Currently Amended) A method according to claim 44, wherein said TPEN prevents inhibits metastatic cellular invasion in said mammal.

46. (Currently Amended) A method according to claim 44, wherein said TPEN prevents inhibits cancerous cell migration in said mammal.

47. (Currently Amended) A method according to claim 44, wherein said TPEN is [[in]] at a concentration of 0.001-100 micromolar.

48. (Currently Amended) A method according to claim 44, wherein said TPEN selectively inhibits angiogenesis or vasculogenesis prevents capillary formation in tumor and cancerous cells in said mammal.

49. (Currently Amended) A method according to claim 48, wherein said inhibiting angiogenesis or vasculogenesis preventing capillary formation inhibits the spread of cancer in said mammal.

50. (Previously Presented) A method according to claim 48, wherein said TPEN is lipid soluble.

51. (Previously Presented) A method according to claim 44, wherein said TPEN has a higher affinity for divalent zinc ions than for other divalent metallic ions.

52. (Currently Amended) A method according to claim 51, wherein said higher affinity avoids chelation of calcium enables normal physiological function in said mammal.

53. (Currently Amended) A method according to claim 44, wherein said method further prevents or treats a disease selected from the group consisting of primary malignancy, carcinoma, Hodgkin's disease, lymphoma, and a hematological disease, angiogenesis, vasculogenesis, tumor cellular invasion, and tumor metastasis.

54. (Previously Presented) A method according to claim 44, wherein said TPEN permeates across cell membranes.

55. (Currently Amended) A method according to claim 44, wherein said TPEN or derivative thereof is complexed with a metal to form a TPEN-metal complex.

56. Canceled.